Author

Jürgen Terhaag

Observed names: J Terhaag, J. Terhaag, Terhaag, Jürgen 1962-

OpenAlex ID: A5076983046

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 480

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 166

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

2014 · G. von Minckwitz, G. von Minckwitz, et al. · Annals of Oncology · 137

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

2021 · R. Charles Coombes, Holly Tovey, et al. · JAMA Oncology · 51

Abstract LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study

2025 · Sibylle Loibl, Marc Thill, et al. · Clinical Cancer Research · 10

Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study

2023 · Nadia Harbeck, Denise Wrobel, et al. · Breast Care · 9

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

2025 · Volkmar Müller, Manuel Hörner, et al. · The Breast · 5

Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al. · Clinical Cancer Research · 2

Abstract P3-11-22: Extended adjuvant neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine – interim analysis of the multinational, prospective, non-interventional study ELEANOR (n=300)

2025 · Diana Lüftner, Denise Wrobel, et al. · Clinical Cancer Research · 2

Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

2023 · Rupert Bartsch, Nadia Harbeck, et al. · Cancer Research · 1

Tattoo-assoziierte Lymphadenopathie als Differenzialdiagnose bei unilateraler axillärer Lymphknotenvergrößerung

2026 · Evelina Juodiene, Fidan Hasanova, et al. · Geburtshilfe und Frauenheilkunde

Expression VIII: Final Results of the Individual Perception and Level of Information of Patients with Borderline Tumors of the Ovary

2026 · Sara Alavi-Demirci, Laura N. Beckmann, et al. · Current Oncology

Unilaterale axilläre Lymphadenopathie im Zusammenhang mit einer Tätowierung

2026 · F Hasanova, E Juodiene, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

EXPRESSION VIII: final results of the individual perception and level of information of patients with borderline tumor of the ovary

2026 · Sara Alavi-Demirci, Hannah Woopen, et al. · International Journal of Gynecological Cancer

Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

2025 · Thomas E. Mürdter, Werner Schroth, et al.

2022-RA-576-ESGO Expression VIII – first study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 321 patients

2022 · Laura Naomi Beckmann, Sara Alavi, et al. · International Journal of Gynecological Cancer

Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

2022 · Diana Lüftner, Rupert Bartsch, et al. · Cancer Research

Works count: 27

Citation count: 863

H-index: 6

I10-index: 5